Superbugs Threaten Millions Of Lives And $2 Trillion Loss By 2050, Study Warns
The UK government-funded research, conducted by the Center for Global Development think tank, reveals that rising antimicrobial resistance (AMR) could cause annual global GDP losses of around \$1.7 trillion over the next 25 years. Wealthy nations such as the US, UK, and EU are expected to face some of the heaviest economic and health impacts.
The findings have sparked criticism over recent international aid cuts. The UK government recently announced the end of funding for the Fleming Fund, which helps combat AMR in low- and middle-income countries. Similarly, the Trump administration confirmed \$9 billion in cuts to its foreign aid budget, while several European nations have also reduced overseas aid spending.
Experts say such measures are short-sighted, as tackling AMR globally is vital to protect health systems and economies worldwide. Without urgent action, drug-resistant infections could become one of the biggest health and economic threats of the century.
Anthony McDonnell, the lead author of the research and a policy fellow at the Center for Global Development, told The Guardian:"When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends.
"However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research.
"Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries.
"This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns."
The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and the UK $58.6bn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
9 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Hans India
a day ago
- Hans India
Indian genetics demand tailored obesity solutions, finds new global study led by CSIR-CCMB
A recent international study led by the Centre for Cellular and Molecular Biology (CSIR-CCMB) in Hyderabad has revealed that lifestyle-based interventions or targeted nutrient supplementation could be more effective for Indians at genetic risk of obesity than generic global approaches. The research highlights a significant genetic variation in obesity risk between Indian and European populations, underlining the need for culturally and biologically relevant health strategies. The study, spearheaded by Dr. Giriraj Ratan Chandak and his team at CSIR-CCMB, forms part of a major global research initiative involving 600 scientists from over 500 institutions. Drawing on genetic data from more than 5 million individuals, including inputs from the GIANT consortium and 23andMe, the study explored how genetic and lifestyle factors combine to influence obesity. A key finding of the study was that the widely used Polygenic Risk Score (PRS)—a genetic test designed to predict obesity—performs more accurately in populations of European ancestry than in those with South Asian ancestry, including Indians. While many obesity-related gene variants identified in Europeans were also tested on Indian samples, most showed limited predictive power, reaffirming the unique nature of Indian genetic makeup. To dig deeper, the researchers analysed genome data from Indian individuals—both diabetics and non-diabetics—who have been monitored over the past two decades. They discovered a distinct pattern of central or abdominal obesity in Indians, unlike the more generalized obesity seen in Western populations. Interestingly, individuals with higher genetic risk for obesity responded better to lifestyle interventions like diet and exercise. However, they were also more prone to weight regain once those interventions ended. 'This finding mirrors earlier studies on height, where European genetic markers had limited applicability to Indians. It appears that diet, nutrition, and environment might play an equally, if not more, critical role in determining obesity in Indians,' said Dr. Chandak. Using Indian genomic data, the team developed a more region-specific PRS to model obesity risk and improve early detection, especially among children. The refined model can predict adulthood obesity by the age of five, making it twice as effective as older models. This breakthrough could enable early preventive measures among genetically vulnerable children, a move that could significantly reduce the burden of obesity-linked diseases such as diabetes and hypertension in India. 'This is not just a test. It's a predictive tool for proactive care,' said Assistant Professor Roelof Smit from the NNF Centre for Basic Metabolic Research at the University of Copenhagen and lead author of the global study, published in Nature Medicine. 'By identifying risk early, especially before lifestyle habits solidify, we can dramatically improve health outcomes.' The findings reiterate that while genetics do play a role, customised lifestyle strategies are critical for Indian populations. The future of obesity prevention in India may rest in precision medicine, where treatment plans are based not just on global data but on uniquely Indian insights.
